Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
July 17, 2006
- SEMINAR
July 17, 2006
- 116 Ingredients/402 Products Added in GE Drug Listing
July 17, 2006
- Taiyo Has Most GE Drugs Listed for 11th Year in a Row
July 17, 2006
- Most Generics Listed in 2006 Available in All Specifications
July 17, 2006
- Original Makers Preparing for Competition with Generics
July 17, 2006
- TOPICS 2 articles
July 17, 2006
- Marketing Companies Must Ally to Survive: Mr Eguchi
July 17, 2006
- Japan Exchanges Opinions with Chinese Regulatory Authorities
July 17, 2006
- Ain Pharmaciez Sets Up Generic Drug Wholesaler
July 17, 2006
- REGULATORY NEWS IN BRIEF
July 17, 2006
- PhRMA Applauds US Opposition for Annual NHI Price Revision
July 17, 2006
- JPA to Survey GE Drug Use in April-May
July 17, 2006
- Biliary Tract Cancer Added as an Indication of Gemzar
July 17, 2006
- OPINION：Conquering the Stress of Change
July 17, 2006
- Alfresa HD to Focus on Low-cost Operations: Mr Watanabe
July 17, 2006
- Astellas Pharma's R&D to Focus on 3 Promising Products
July 17, 2006
- NHO Slims Its Formulary, Retains Amlodin, Eliminates Norvasc
July 17, 2006
- TeGenero Files for Bankruptcy
July 17, 2006
- Novartis Pharma Taking Steps to Protect Diovan's Sales, Share
July 17, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…